Showing 1921-1930 of 2123 results for "".
- First Participant Enrolls in Clinical Trial of Vidofludimus Calcium for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/first-participant-enrolls-in-clinical-trial-of-vidofludimus-calcium-for-relapsing-multiple-sclerosis/2469799/The twin phase 3 clinical trials ENSURE-1 clinical trial (NCT05134441) of vidofludimus calcium (IMU-838; Immunic Therapeutics, New York, NY) enrolled the first participant for potential trea
- First Participant Dosed of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/first-participant-dosed-of-novel-chimeric-cell-therapy-for-duchenne-muscular-dystrophy/2469789/The first patient has been treated in a phase 1 clinical study of dystrophin-expressing chimeric cells (DEC)(DT-DEC01; Dystrogen Therapeutics, Miami, FL) for the treatment of Duchenne muscular dystrophy (DMD). The first participant, age 6 years, received an infusion of DEC, tolerated th
- Diagnostic Delay for Focal Epilepsy Is Significantly Longer in Children and Adolescentshttps://practicalneurology.com/news/diagnostic-delay-for-focal-epilepsy-is-significantly-longer-in-children-and-adolescents/2469768/Retrospective analysis of data from the Human Epilepsy Project, showed time to diagnosis of epilepsy in people with focal seizure onset before vs after age 18 years was a median 340 vs 207 days (P=.012). For those who had only nonmotor focal seizures, the mean time to diagnosis was 1,019
- Evidence of Utility of Gene Testing for Children with Unexplained Epilepsy Continues to Growhttps://practicalneurology.com/news/evidence-of-utility-of-gene-testing-for-children-with-unexplained-epilepsy-continues-to-grow/2469767/Analysis of 152 children with unexplained epilepsy treated at a single institution had care that was substantially affected by genetic evaluation, suggesting any child with unexplained epilepsy should have such an evaluation. Of those tested, 72% had changes in medical care in at
- First Participant Enrolled in Phase 3 Study of Vidofludimus Calcium for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/first-participant-enrolled-in-phase-3-study-of-vidofludimus-calcium-for-relapsing-multiple-sclerosis/2469761/The first participant has enrolled in the phase 3 ENSURE-1 clinical trial (NCT05134441) of vidofludimus calcium (IMU-838; Immunic Therapeutics, New York, NY) for potential treatment of relapsing m
- FDA Accepts Investigational New Drug Application and Grants Fast Track Designation of Trehalose for Spinocerebellar Ataxia Treatmenthttps://practicalneurology.com/news/fda-accepts-investigational-new-drug-application-and-grants-fast-track-designation-of-trehalose-for-spinocerebellar-ataxia-treatment/2469747/The Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application to trehalose (SLS-005; Seelos Therapeutics, New York, NY) for spinocerebellar ataxia (SCA) treatment. The FDA has granted the program Fast Track designation for SCA, and trehalose has previously rec
- Autologous Mesenchymal Stem Cells Expressing Neurotrophic Factors Improved Function and Biomarkers in Progressive Multiple Sclerosishttps://practicalneurology.com/news/autologous-mesenchymal-stem-cells-expressing-neurotrophic-factors-improved-function-and-biomarkers-in-progressive-multiple-sclerosis/2469728/In a trial (NCT03799718) of autologous neurotrophic mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY), 18 individuals with progressive MS were treated, and 16 c
- Ocrelizumab Reduced Disability Progression in Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosishttps://practicalneurology.com/news/ocrelizumab-reduced-disability-progression-in-relapsing-multiple-sclerosis-and-primary-progressive-multiple-sclerosis/2469717/Individuals with relapsing multiple sclerosis (RMS) who were treated with ocrelizumab (Ocrevus; Genentech, South San Francisco, CA) for 7.5 years vs 5.5 years (after ~2 years on interferon β) had a 35% lower chance of needing a walking aid (5.2% vs. 7%, 95% CI: 0.44–0.97; P=.034). The
- First Participant Treated With Vidofludimus in Phase 2 Trialhttps://practicalneurology.com/news/phase-3-vidofludimus-calcium-trial-initiates-first-participant-dosage/2469705/A phase 2 trial for vidofludimus calcium (VFC)(IMU-838; Immunic, New York, NY) has been initiated with the first participant treated for progressive multiple sclerosis (PMS). The CALLIPER trial (NCT05
- Huntington Disease Trial of New Antisense Oligonucleotide Therapy Begins Dosinghttps://practicalneurology.com/news/huntington-disease-trial-of-new-antisense-oligonucleotide-therapy-begins-dosing/2469685/The first participant has been treated in the phase 1b/2a SELECT-HD clinical trial evaluating an investigational stereopure antisense oligonucleotide (ASO) (WVE-003; Wave Life Sciences, Cambridge, MA) as a treatment for Huntington disease (HD). The ASO is designed to target a single nucleotide po